The Journal of rheumatology. Supplement最新文献_第5页

Mortality Rates in Patients With Ankylosing Spondylitis With and Without Extraarticular Manifestations and Comorbidities: A Retrospective Cohort Study 有或无关节外表现和合并症的强直性脊柱炎患者的死亡率:一项回顾性队列研究

The Journal of rheumatology. Supplement Pub Date : 2022-04-15 DOI: 10.3899/jrheum.210909

E. Kelty, M. Ognjenovic, W. Raymond, C. Inderjeeth, H. Keen, D. Preen, J. Nossent

{"title":"Mortality Rates in Patients With Ankylosing Spondylitis With and Without Extraarticular Manifestations and Comorbidities: A Retrospective Cohort Study","authors":"E. Kelty, M. Ognjenovic, W. Raymond, C. Inderjeeth, H. Keen, D. Preen, J. Nossent","doi":"10.3899/jrheum.210909","DOIUrl":"https://doi.org/10.3899/jrheum.210909","url":null,"abstract":"Objective. To examine mortality rates in hospitalized patients with ankylosing spondylitis (AS) and the association of extraarticular manifestations (EAMs) and comorbidities with mortality rates. Methods. This study was a retrospective, population-based cohort study using linked administrative data from patients with AS who were hospitalized (n = 1791) and patients in a matched comparison group (n = 8955). Mortality data for patients were obtained from the Western Australia Death Register. The presence of EAMs and comorbidities was identified from hospital records. Mortality rates were compared between the 2 groups using Cox proportional hazard models overall and stratified by a history of EAMs, comorbidities, and smoking status. Results. Crude mortality rates were significantly higher among patients with AS than among patients in the comparison group (hazard ratio [HR] 1.85, 95% CI 1.62–2.12), with excess mortality in the AS group associated with cardiovascular disease (CVD; HR 5.32, 95% CI 3.84–7.35), cancer (HR 1.68, 95% CI 1.27–2.23), external causes (HR 3.92, 95% CI 2.28–6.77), and infectious diseases (HR 25.92, 95% CI 7.50–89.56). When patients were stratified by history of EAMs, CVD, and smoking, the risk of mortality was elevated in patients both with and without each risk factor. Among patients with AS, histories of CVD (HR 6.33, 95% CI 4.79–8.38), diabetes (HR 2.81, 95% CI 1.99–3.95), smoking (HR 1.49, 95% CI 1.18–1.89), and EAMs (HR 1.62, 95% CI 1.24–2.11) were associated with an increased risk of mortality. Conclusion. The presence of comorbidities, EAMs, and smoking contributes to an increased risk of all-cause mortality among patients with AS who are hospitalized compared to patients in the comparison group. These results support the need to prevent or reduce the occurrence of comorbidities and smoking in patients with AS.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"7 1","pages":"688 - 693"},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87851693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Monitoring of Disease Activity With a Smartphone App in Routine Clinical Care in Patients With Axial Spondyloarthritis 应用智能手机App监测轴型脊柱炎患者的疾病活动度

The Journal of rheumatology. Supplement Pub Date : 2022-04-15 DOI: 10.3899/jrheum.211116

Robin Kempin, J. Richter, Anna Schlegel, X. Baraliakos, S. Tsiami, B. Buehring, D. Kiefer, J. Braun, U. Kiltz

{"title":"Monitoring of Disease Activity With a Smartphone App in Routine Clinical Care in Patients With Axial Spondyloarthritis","authors":"Robin Kempin, J. Richter, Anna Schlegel, X. Baraliakos, S. Tsiami, B. Buehring, D. Kiefer, J. Braun, U. Kiltz","doi":"10.3899/jrheum.211116","DOIUrl":"https://doi.org/10.3899/jrheum.211116","url":null,"abstract":"Objective To investigate the performance of a health app with respect to usability, adherence, and equivalence of data in daily care of patients with axial spondyloarthritis (axSpA). Methods Consecutive patients with axSpA were asked to export patient-reported outcomes (PRO) electronically with the AxSpA Live App regularly every 2 weeks over a period of 6 months. The first clinical visit was followed by 2 further personal visits after 3 and 6 months. Patients completed paper-based PRO at every visit; they also completed the Mobile App Rating Scale and the System Usability Scale after 3 and 6 months. Results Of 103 patients with axSpA, 69 agreed to participate (67.0%): age 41.5 (11.3) years, 58.0% male, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 4.3 (2.0), and 76.8% treated with biologic disease-modifying antirheumatic drugs. Patients’ adherence to regular app exports was 29.0% and 28.4% after 3 and 6 months, respectively. Significant predictors for good adherence were high disease activity (P = 0.02) and older age (P = 0.04). No systematic differences between digital and paper-based BASDAI scores were found (intraclass correlation coefficients 0.99 [95% CI 0.98-0.99]). Performance of the app was rated as good. Conclusion Collection of digital PROs by AxSpA Live App may be successfully used in patients with axSpA with high disease activity. Our study showed equivalence of digital data, but adherence to the app after 6 months was poor. Higher disease activity and older age resulted in increased adherence to the app. This suggests that the use of health apps like this should concentrate on more severely affected patients.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"11 1","pages":"878 - 884"},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87658171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Challenges in the Diagnosis and Assessment of Psoriatic Arthritis. 银屑病关节炎诊断与评估的挑战。

The Journal of rheumatology. Supplement Pub Date : 2022-04-15 DOI: 10.3899/jrheum.211337

A. Ogdie, C. Lindsay, P. Mease, K. Callis Duffin, C. Rosen, S. Siebert

引用次数: 0

Whole-Body Macrophage Positron Emission Tomography Imaging for Disease Activity Assessment in Early Rheumatoid Arthritis 巨噬细胞正电子发射断层成像在早期类风湿关节炎疾病活动性评估中的应用

The Journal of rheumatology. Supplement Pub Date : 2022-04-15 DOI: 10.3899/jrheum.210928

N. Verweij, J. de Jongh, M. Wee, G. Zwezerijnen, M. Yaqub, A. Voskuyl, A. Lammertsma, D. van Schaardenburg, M. Boers, W. Lems, C. J. van der Laken

{"title":"Whole-Body Macrophage Positron Emission Tomography Imaging for Disease Activity Assessment in Early Rheumatoid Arthritis","authors":"N. Verweij, J. de Jongh, M. Wee, G. Zwezerijnen, M. Yaqub, A. Voskuyl, A. Lammertsma, D. van Schaardenburg, M. Boers, W. Lems, C. J. van der Laken","doi":"10.3899/jrheum.210928","DOIUrl":"https://doi.org/10.3899/jrheum.210928","url":null,"abstract":"Objective To investigate the potential of whole-body positron emission tomography/computed tomography (PET/CT) with a macrophage tracer to image arthritis in patients with early rheumatoid arthritis (RA). Methods Thirty-five previously untreated, clinically active patients with early RA underwent whole-body PET/CT scanning with the macrophage tracer (R)-[11C]PK11195 in addition to clinical assessment (Disease Activity Score in 44 joints [DAS44]). Tracer uptake was assessed quantitatively as standardized uptake values (SUVs). In addition, 2 readers blinded to clinical assessment visually scored tracer uptake in joints. Clinical and PET variables were compared using Cohen , linear regression/correlation, and t tests, where appropriate. Results All but 1 patient showed enhanced tracer uptake in at least 1 joint. Twelve percent of all joints (171/1470) were visually positive on the PET scan, most frequently the small joints in feet (40%) and hands (37%), followed by wrists (15%). Correlations of visual scores with clinical findings both at patient and joint levels were absent or weak. In contrast, average SUVs in the hands, feet, and whole body showed significant correlations with DAS44 scores, with the best correlation seen in the feet (R2 = 0.29, P < 0.01). Conclusion Clinically active patients with early RA had increased joint uptake of a macrophage PET tracer, especially in the feet. Quantitative, but not visual PET measures of whole body and joint groups, particularly the feet, showed moderate and statistically significant correlations with clinical outcome.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"59 1","pages":"871 - 877"},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86123964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: Interim Report of Postmarketing Surveillance in Japan 他克莫司用于多肌炎或皮肌炎相关的间质性肺炎患者:日本上市后监测的中期报告

The Journal of rheumatology. Supplement Pub Date : 2022-04-15 DOI: 10.3899/jrheum.210322

M. Kuwana, N. Wakasugi, Toshinori Furuya, S. Uno, T. Suda

{"title":"Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: Interim Report of Postmarketing Surveillance in Japan","authors":"M. Kuwana, N. Wakasugi, Toshinori Furuya, S. Uno, T. Suda","doi":"10.3899/jrheum.210322","DOIUrl":"https://doi.org/10.3899/jrheum.210322","url":null,"abstract":"Objective. The calcineurin inhibitor tacrolimus has been approved in Japan for the treatment of interstitial pneumonia (IP) in patients with polymyositis (PM) and dermatomyositis (DM). Postmarketing surveillance was initiated to examine long-term outcomes of immunosuppressive regimens containing tacrolimus in real-world settings. Methods. Observational, prospective, postmarketing surveillance is ongoing in 179 patients with PM/DM-associated IP initiating treatment with tacrolimus. We report interim findings after 2 years of follow-up. Cumulative overall survival was assessed using Kaplan-Meier analysis. Potential prognostic factors for mortality were assessed by univariate Cox proportional hazards analysis. Results. A total of 170 patients were included in this analysis. At the time of starting treatment with tacrolimus, almost all patients were receiving corticosteroids (98.8%), and cyclophosphamide was additionally used in 42 patients (24.7%). Forty-nine patients (28.8%) discontinued tacrolimus during follow-up, mainly due to loss to follow-up, patient death, and adverse events. Mean (SD) oral corticosteroid dose decreased from 32.4 (21.6) mg/day at baseline to 7.6 (4.2) mg/day at 2 years. Overall survival at 2 years was 90.3%; corresponding progression-free survival was 62.5%. Factors found to be associated with all-cause mortality included diagnosis of clinically amyopathic DM (hazard ratio [HR] 9.04, 95% CI 1.18-69.51 vs PM), ferritin level 500 to < 1500 ng/mL (HR 8.61, 95% CI 2.51-29.45 vs < 500 ng/mL), and presence of antimelanoma differentiation-associated gene 5 antibodies (HR 8.16, 95% CI 1.03–64.47 vs absence). Conclusion. Immunosuppressive regimens containing tacrolimus appear useful for the management of IP in patients with PM/DM. [ClinicalTrials.gov: NCT02159651]","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"19 1","pages":"707 - 718"},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79391434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

The Challenge of Addressing the Rheumatology Workforce Shortage 解决风湿病人力短缺的挑战

The Journal of rheumatology. Supplement Pub Date : 2022-04-15 DOI: 10.3899/jrheum.220300

E. Miloslavsky, Bethany Marston

引用次数: 3

Post SARS-CoV-2 Vaccine Chilblains-like Lesions SARS-CoV-2疫苗后冻疮样病变

The Journal of rheumatology. Supplement Pub Date : 2022-04-15 DOI: 10.3899/jrheum.210996

R. Mungmunpuntipantip, V. Wiwanitkit

引用次数: 0

Treatment of Childhood-onset Proliferative Lupus Nephritis in the 21st Century: A Call to Catch Up With the Evidence 21世纪儿童性增殖性狼疮性肾炎的治疗:追赶证据的呼唤

The Journal of rheumatology. Supplement Pub Date : 2022-04-01 DOI: 10.3899/jrheum.220196

D. Noone, E. Silverman

引用次数: 0

Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects. 基础科学1。银屑病关节炎治疗反应和关节损伤进展的生物标志物:2个行业- grappa项目的最新进展

The Journal of rheumatology. Supplement Pub Date : 2022-04-01 DOI: 10.3899/jrheum.211320

J. Waddington, Orla Coleman, P. Mease, V. Chandran, D. O'Sullivan, O. FitzGerald, S. Pennington

引用次数: 0

Who Are We to Decide That the Unvaccinated Don’t Deserve Care? 我们凭什么决定未接种疫苗的人不值得照顾?

The Journal of rheumatology. Supplement Pub Date : 2022-04-01 DOI: 10.3899/jrheum.220110

C. Barnabe

引用次数: 1